Skip to content

Ocular Pressure in Steroid-treated Dermatology Patients

Intraocular Pressure in Corticosteroid-treated Dermatology Patients

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01759914
Enrollment
25
Registered
2013-01-03
Start date
2012-09-30
Completion date
2013-07-31
Last updated
2014-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intra-ocular Pressure, Topical Corticosteroid-treated Dermatology Patients

Brief summary

Ocular hypertension and glaucoma are eye conditions associated with abnormally high fluid pressure in the eye (called intraocular pressure or IOP). If left untreated, the elevated IOP may eventually cause damage to the nerve of the eye and potential impairment of vision. The use of certain drugs has been identified as a risk factor for raised IOP, including various forms of administration of corticosteroids. Corticosteroids can also lead to cataract, which is clouding of the lens in the eye that can affect vision. In this research study, we would like to find out whether the use of corticosteroids in our dermatology clinic leads to raised IOP, in order to identify patients at risk and to allow them to be more closely monitored than others. It is important to identify those patients who have a corticosteroid-induced pressure rise early enough to prevent them from permanent glaucomatous visual loss.

Interventions

DRUGSuperpotent topical steroid

Sponsors

University Hospital, Geneva
CollaboratorOTHER
University Hospitals Coventry and Warwickshire NHS Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients on whom corticosteroid treatment is being introduced for a duration of at least 12 weeks

Exclusion criteria

* pregnant women * patients already under glaucoma treatment * patients unable to give informed written consent or those unable to cooperate fully with the assessments

Design outcomes

Primary

MeasureTime frameDescription
Change in intraocular pressure from baselineafter 1, 2 and 3 monthsMeasurements will be done at 28 (+/- 7 days) days, 56 (+/- 7 days) days, and 90 (+/- 7 days)days after initiation of topical steroids.

Secondary

MeasureTime frameDescription
Whether there is any clinical evidence of cataract at the final visit of the study.After 1, 2 and 3 monthsMeasurements will be done at 28 (+/- 7 days) days, 56 (+/- 7 days) days, and 90 (+/- 7 days)days after initiation of topical steroids.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026